Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin

Graphical abstract

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2015-02, Vol.62 (2), p.294-302
Hauptverfasser:	Feld, Jordan J, Jacobson, Ira M, Jensen, Donald M, Foster, Graham R, Pol, Stanislas, Tam, Edward, Jablkowski, Maciej, Berak, Hanna, Vierling, John M, Yoshida, Eric M, Perez-Gomez, Héctor R, Scalori, Astrid, Hooper, Gregory J, Tavel, Jorge A, Navarro, Mercidita T, Shahdad, Saba, Kulkarni, Rohit, Pogam, Sophie Le, Nájera, Isabel, Eng, Simon, Lim, Chin Yin, Shulman, Nancy S, Yetzer, Ellen S
Format:	Artikel
Sprache:	eng
Schlagworte:	Cytochrome P-450 CYP3A Inhibitors - administration & dosage Danoprevir Dose-Response Relationship, Drug Drug Administration Schedule Drug Carriers Drug Therapy, Combination Female Follow-Up Studies Gastroenterology and Hepatology Genotype Genotype 1 HCV Hepacivirus - genetics Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Interferon-alpha - administration & dosage Lactams - administration & dosage Male Mericitabine Middle Aged Non-responders Peginterferon/ribavirin Polyethylene Glycols - administration & dosage Quad therapy Recombinant Proteins - administration & dosage Retrospective Studies Ribavirin - administration & dosage Ritonavir - administration & dosage RNA, Viral - genetics Sulfonamides - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!